PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Genmab B.V.

USPTO PatentsView assignee record - 13 granted patents across 5 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Genmab ranks #21,176 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 5 technology areas.

#21,176
of 49,997 US assignees by volume
44th percentile
by Innovation Score (33.3/100)
18.2
avg claims per patent
+800%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R21176 · Foreign Corporation #21,176 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 13 grants
  • MID-PACK #21,176/49,997
  • PHOTO-FINISH Galectin Therapeutics
  • CPC-NARROW C07K · 5 areas
  • INNOV-THIN 33.3/100
  • CLAIMS-RICH 18.2 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +800% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Galectin Therapeutics, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Genmab’s 33.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Genmab

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Genmab's Innovation Score is 33.3/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Genmab?

Each dot is one of Genmab’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Genmab’s own 18.2 claims/patent is ABOVE the 15.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Genmab vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 12.912.91313.1 5101520 Granted patents (volume) Avg claims / patent G.W. Lisk Company, Inc. - 13, 15G W LiskGalectin Therapeutics, Inc. - 13, 16.46Galectin Therapeu…General Dynamics Ordnance AND Tactical SYSTEMS—CANADA, Inc. - 13, 18.54General Dynamics…General Test Systems Inc. - 13, 16.46General Test Syst…Genome Research Limited - 13, 14.08Genome ResearchGensquare LLC - 13, 7.85GensquareGeophysical Survey Systems, Inc. - 13, 15.31Geophysical Surve…Gilrose Pharmaceuticals, LLC - 13, 15.85Gilrose Pharmaceu…Genmab B.V. - 13, 18.23Genmab B V
Genmab vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Genmab's grants concentrate

Genmab B.V. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2017. By volume, Genmab sits between G.W. Lisk Company, Inc. and Gilrose Pharmaceuticals, LLC.

Genmab's three-year grant acceleration

Genmab B.V. shows 4 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Genmab's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Genmab holds 13 patents at rank #21,167, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Genmab

By rank, the assignees closest to #21,167 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Genmab's primary technology class.

Genmab's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 201720202021202220242025 3
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Genmab B.V. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 7.7%
2020 2 15.4%
2021 3 23.1%
2022 2 15.4%
2024 2 15.4%
2025partial year 3 23.1%

Which technologies does Genmab B.V. patent most?

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Genmab B.V.'s patent record in context - here's where to go next.

  • Genmab B.V.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
  • Ranked #21,176 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Genmab B.V. against G.W. Lisk Company, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 33.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.